You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Guidelines and Advice
Status: Current
ID: MCC
Jun 2006
Guidelines and Advice
Status: Archived
ID: 20-1
Aug 2006
Guidelines and Advice
Status: Education and Information
ID: 1-24 Version 2
Version: 2
May 2006
Guidelines and Advice
Status: Archived
ID: CED 3
Jan 2006
Guidelines and Advice
Status: Archived
ID: CED 2
Version: 2
Jan 2006
Guidelines and Advice
Status: Archived
ID: 13-8
Oct 2006
Guidelines and Advice
Status: Archived
ID: HPVTest
Apr 2006
Guidelines and Advice
Status: Current
ID: GL-C50-03
Apr 2006
Statistical Reports
May 2006
Drug
Other Name(s): Unituxin®
Quick Link(s):
Drug Monograph
Jun 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
Exceptional Access Program
    venetoclax - in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2023

Pages